Literature DB >> 2754552

Effect on renal function of essential fatty acid supplementation in cystic fibrosis.

B Strandvik1, U Berg, A Kallner, E Kusoffsky.   

Abstract

Changes in renal hemodynamics, sodium homeostasis, renal acidifying capacity, and aldosterone excretion were studied before and after long-term intravenous essential fatty acid supplementation for a period of 3 years in 11 patients with cystic fibrosis. The mean (+/- SD) glomerular filtration rate was high at the start of the study (133 +/- 18 ml/min/1.73 m2 body surface area) and decreased significantly (p less than 0.05) to within normal values after 1 year of essential fatty acid supplementation. The urinary elimination of an oral sodium load initially was very low (3.6 +/- 2.5 mmol/hr/1.73 m2 body surface area vs control subjects' values of 7.9 +/- 2.0; p less than 0.001) and increased during treatment but was not normalized (p less than 0.05 vs control subjects' values). Free water clearance and distal tubular sodium delivery, which were significantly decreased before treatment (p less than 0.01 and p less than 0.001 vs control subjects' values, respectively) did not increase significantly. The mean urinary aldosterone excretion did not significantly differ from that in control subjects before and after treatment. The acidifying capacity was disturbed, indicating a low renal bicarbonate threshold, and was changed during treatment in only 2 of 10 patients. These data indicate that essential fatty acid deficiency may contribute to the renal disturbances in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2754552     DOI: 10.1016/s0022-3476(89)80072-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 2.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

3.  Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice.

Authors:  Birgitta Strandvik; Wanda K O Neal; Mohamed A Ali; Ulf Hammar
Journal:  Exp Biol Med (Maywood)       Date:  2018-03

4.  Renal function in pediatric cystic fibrosis patients in the first decade of life.

Authors:  Chanel Prestidge; Mark A Chilvers; A George F Davidson; Eva Cho; Vanessa McMahon; Colin T White
Journal:  Pediatr Nephrol       Date:  2010-12-29       Impact factor: 3.714

5.  Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?

Authors:  Miki Susanto; Leslie Z Benet
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

6.  Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; Paul R Gallagher; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-11       Impact factor: 2.839

7.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

8.  Serum fatty acid profiles in cystic fibrosis patients and their parents.

Authors:  A B Christophe; W J Warwick; R T Holman
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

9.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.

Authors:  B A Christensson; I Nilsson-Ehle; B Ljungberg; A Lindblad; A S Malmborg; L Hjelte; B Strandvik
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Authors:  Birgitta Strandvik
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.